Header Logo

Connection

Arthur Krieg to Adjuvants, Immunologic

Back to Details
This is a "connection" page, showing publications Arthur Krieg has written about Adjuvants, Immunologic.
Arthur Krieg
Connection Strength
7.577
Adjuvants, Immunologic
  1. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012 Apr; 22(2):77-89.
    View in: PubMed
    Score: 0.337
  2. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009 Mar 28; 61(3):195-204.
    View in: PubMed
    Score: 0.272
  3. Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008 Oct; 21(8):434-9.
    View in: PubMed
    Score: 0.266
  4. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul; 4(3):289-94.
    View in: PubMed
    Score: 0.244
  5. Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M, Krieg AM. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine. 2006 Aug 28; 24(35-36):6155-62.
    View in: PubMed
    Score: 0.225
  6. Waag DM, McCluskie MJ, Zhang N, Krieg AM. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun. 2006 Mar; 74(3):1944-8.
    View in: PubMed
    Score: 0.223
  7. McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol. 2006; 311:155-78.
    View in: PubMed
    Score: 0.220
  8. Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C, Krieg AM. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004 Jun; 48(6):2314-7.
    View in: PubMed
    Score: 0.197
  9. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004 Mar; 6(2):88-95.
    View in: PubMed
    Score: 0.194
  10. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, W?llner M, Tluk S, Hartmann H, Kritzler A, M?ller C, Schetter C, Krieg AM. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res. 2004; 10(6):431-8.
    View in: PubMed
    Score: 0.192
  11. Ray NB, Krieg AM. Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. Infect Immun. 2003 Aug; 71(8):4398-404.
    View in: PubMed
    Score: 0.186
  12. Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis. 2003; 35(9):653-9.
    View in: PubMed
    Score: 0.179
  13. Krieg AM, Guga P, Stec W. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003; 13(6):491-9.
    View in: PubMed
    Score: 0.179
  14. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol. 2002 May 01; 168(9):4711-20.
    View in: PubMed
    Score: 0.171
  15. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol. 2001 Sep 01; 167(5):2921-8.
    View in: PubMed
    Score: 0.163
  16. Krieg AM. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev. 2001 Jun; 11(3):181-8.
    View in: PubMed
    Score: 0.160
  17. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb; 3(1):15-24.
    View in: PubMed
    Score: 0.157
  18. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000 Feb 01; 164(3):1617-24.
    View in: PubMed
    Score: 0.146
  19. Krieg AM. CpG oligonucleotides as immune adjuvants. Ernst Schering Res Found Workshop. 2000; (30):105-18.
    View in: PubMed
    Score: 0.145
  20. Krieg AM, Yi AK. Rescue of B cells from apoptosis by immune stimulatory CpG DNA. Springer Semin Immunopathol. 2000; 22(1-2):55-61.
    View in: PubMed
    Score: 0.145
  21. Krieg AM. Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000; 22(1-2):97-105.
    View in: PubMed
    Score: 0.145
  22. Krieg AM. CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb; 7(2):64-5.
    View in: PubMed
    Score: 0.136
  23. Yi AK, Krieg AM. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998 Nov 01; 161(9):4493-7.
    View in: PubMed
    Score: 0.134
  24. Reeman S, Gates AJ, Pulford DJ, Krieg A, Ulaeto DO. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant. Viruses. 2017 12 09; 9(12).
    View in: PubMed
    Score: 0.126
  25. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30; 94(20):10833-7.
    View in: PubMed
    Score: 0.124
  26. Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW. CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. Int J Antimicrob Agents. 2013 Dec; 42(6):587-8.
    View in: PubMed
    Score: 0.094
  27. Rees DG, Hartley MG, Green M, Lukaszewski RA, Griffin KF, Atkins HS, Lyons R, Krieg AM, Titball RW. The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. Microb Pathog. 2013 Oct; 63:16-8.
    View in: PubMed
    Score: 0.092
  28. Nguyen DN, Mahon KP, Chikh G, Kim P, Chung H, Vicari AP, Love KT, Goldberg M, Chen S, Krieg AM, Chen J, Langer R, Anderson DG. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci U S A. 2012 Apr 03; 109(14):E797-803.
    View in: PubMed
    Score: 0.085
  29. La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012 Apr 15; 205(8):1294-304.
    View in: PubMed
    Score: 0.084
  30. Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, Krieg AM, Titball RW, Bancroft GJ. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis. 2011 Aug 15; 204(4):636-44.
    View in: PubMed
    Score: 0.081
  31. Krieg AM. AIMing 2 defend against intracellular pathogens. Nat Immunol. 2010 May; 11(5):367-9.
    View in: PubMed
    Score: 0.074
  32. Wang Y, Blozis SA, Lederman M, Krieg A, Landay A, Miller CJ. Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol. 2009 Apr; 16(4):499-505.
    View in: PubMed
    Score: 0.068
  33. Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, Worsham PL, Powell BS, Norris SL, Krieg AM, Adamovicz JJ. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine. 2009 Apr 06; 27(16):2220-9.
    View in: PubMed
    Score: 0.068
  34. Krieg AM, Khan AS, Steinberg AD. Multiple endogenous xenotropic and mink cell focus-forming murine leukemia virus-related transcripts are induced by polyclonal immune activators. J Virol. 1988 Oct; 62(10):3545-50.
    View in: PubMed
    Score: 0.067
  35. Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine. 2008 Sep 02; 26(37):4849-59.
    View in: PubMed
    Score: 0.066
  36. Stewart VA, McGrath S, Krieg AM, Larson NS, Angov E, Smith CL, Brewer TG, Heppner DG. Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin Vaccine Immunol. 2008 Feb; 15(2):221-6.
    View in: PubMed
    Score: 0.063
  37. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15; 179(4):2493-500.
    View in: PubMed
    Score: 0.062
  38. Krieg AM. Toll-free vaccines? Nat Biotechnol. 2007 Mar; 25(3):303-5.
    View in: PubMed
    Score: 0.060
  39. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007; 12(5):741-51.
    View in: PubMed
    Score: 0.059
  40. Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet Immunol Immunopathol. 2007 Jan 15; 115(1-2):24-34.
    View in: PubMed
    Score: 0.058
  41. Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. ChemMedChem. 2006 Sep; 1(9):1007-14.
    View in: PubMed
    Score: 0.058
  42. Nichani AK, Mena A, Kaushik RS, Mutwiri GK, Townsend HG, Hecker R, Krieg AM, Babiuk LA, Griebel PJ. Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. Oligonucleotides. 2006; 16(1):58-67.
    View in: PubMed
    Score: 0.055
  43. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005 Sep 23; 19(14):1473-9.
    View in: PubMed
    Score: 0.054
  44. Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother. 2006 May; 55(5):515-27.
    View in: PubMed
    Score: 0.053
  45. Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E. Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol. 2005 Mar 15; 69(6):981-91.
    View in: PubMed
    Score: 0.052
  46. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
    View in: PubMed
    Score: 0.051
  47. Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol. 2004 Oct 15; 173(8):5148-55.
    View in: PubMed
    Score: 0.051
  48. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004 Oct 01; 173(7):4433-42.
    View in: PubMed
    Score: 0.050
  49. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004 Aug 13; 22(23-24):3136-43.
    View in: PubMed
    Score: 0.050
  50. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun. 2004 Feb; 72(2):949-57.
    View in: PubMed
    Score: 0.048
  51. Hirunpetcharat C, Wipasa J, Sakkhachornphop S, Nitkumhan T, Zheng YZ, Pichyangkul S, Krieg AM, Walsh DS, Heppner DG, Good MF. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine. 2003 Jun 20; 21(21-22):2923-32.
    View in: PubMed
    Score: 0.046
  52. Lenert P, Yi AK, Krieg AM, Stunz LL, Ashman RF. Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. Antisense Nucleic Acid Drug Dev. 2003; 13(3):143-50.
    View in: PubMed
    Score: 0.045
  53. Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, Brasel K, Blazar BR. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood. 2002 Dec 01; 100(12):4169-76.
    View in: PubMed
    Score: 0.043
  54. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol. 2002 Feb 01; 168(3):1212-8.
    View in: PubMed
    Score: 0.042
  55. Pontarollo RA, Rankin R, Babiuk LA, Godson DL, Griebel PJ, Hecker R, Krieg AM, van Drunen Littel-van den Hurk S. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Vet Immunol Immunopathol. 2002 Jan 01; 84(1-2):43-59.
    View in: PubMed
    Score: 0.042
  56. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg AM, Endres S, Hartmann G. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. Eur J Immunol. 2001 Dec; 31(12):3525-34.
    View in: PubMed
    Score: 0.041
  57. Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
    View in: PubMed
    Score: 0.041
  58. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 01; 167(9):4878-86.
    View in: PubMed
    Score: 0.041
  59. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct; 31(10):3026-37.
    View in: PubMed
    Score: 0.041
  60. Chen Y, Zhang J, Moore SA, Ballas ZK, Portanova JP, Krieg AM, Berg DJ. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int Immunol. 2001 Aug; 13(8):1013-20.
    View in: PubMed
    Score: 0.041
  61. Krug A, Rothenfusser S, Hornung V, Jahrsd?rfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul; 31(7):2154-63.
    View in: PubMed
    Score: 0.040
  62. Kovarik J, Bozzotti P, Tougne C, Davis HL, Lambert PH, Krieg AM, Siegrist CA. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology. 2001 Jan; 102(1):67-76.
    View in: PubMed
    Score: 0.039
  63. Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15; 165(12):6889-95.
    View in: PubMed
    Score: 0.039
  64. Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol. 2000 Dec 01; 165(11):6244-51.
    View in: PubMed
    Score: 0.039
  65. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 01; 165(11):6278-86.
    View in: PubMed
    Score: 0.039
  66. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22; 19(7-8):950-7.
    View in: PubMed
    Score: 0.039
  67. Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 08; 19(6):618-22.
    View in: PubMed
    Score: 0.039
  68. Krieg AM, Wagner H. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct; 21(10):521-6.
    View in: PubMed
    Score: 0.038
  69. Davis HL, Suparto II, Weeratna RR, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Smits W, Sajuthi DD. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000 Mar 17; 18(18):1920-4.
    View in: PubMed
    Score: 0.037
  70. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb; 12(1):35-43.
    View in: PubMed
    Score: 0.037
  71. Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10; 1489(1):107-16.
    View in: PubMed
    Score: 0.036
  72. Krieg AM, Yi AK, Hartmann G. Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol Ther. 1999 Nov; 84(2):113-20.
    View in: PubMed
    Score: 0.036
  73. Jones TR, Obaldia N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999 Aug 06; 17(23-24):3065-71.
    View in: PubMed
    Score: 0.035
  74. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999 Aug 03; 96(16):9305-10.
    View in: PubMed
    Score: 0.035
  75. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A. 1999 Jun 08; 96(12):6970-5.
    View in: PubMed
    Score: 0.035
  76. Krieg AM. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb; 1(1):56-63.
    View in: PubMed
    Score: 0.034
  77. Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998 Nov 15; 92(10):3730-6.
    View in: PubMed
    Score: 0.034
  78. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15; 161(6):3042-9.
    View in: PubMed
    Score: 0.033
  79. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998 Jan 15; 160(2):870-6.
    View in: PubMed
    Score: 0.032
  80. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan; 6(1):23-7.
    View in: PubMed
    Score: 0.032
  81. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17; 186(10):1623-31.
    View in: PubMed
    Score: 0.031
  82. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15; 89(8):2994-8.
    View in: PubMed
    Score: 0.030
  83. Nichani AK, Dar MA, Krieg AM, Mirakhur KK, Kaushik RS, Griebel PJ, Manuja A, Townsend HG, Babiuk LA, Mutwiri GK. Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. Vet Immunol Immunopathol. 2007 Feb 15; 115(3-4):357-68.
    View in: PubMed
    Score: 0.015
  84. Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006 Oct; 34(10):1403-12.
    View in: PubMed
    Score: 0.014
  85. Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol. 2005 Jan; 35(1):273-81.
    View in: PubMed
    Score: 0.013
  86. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004 Aug; 72(8):4494-502.
    View in: PubMed
    Score: 0.012
  87. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002 Jun; 3(6):499.
    View in: PubMed
    Score: 0.011
  88. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 05; 32(5):1212-22.
    View in: PubMed
    Score: 0.011
  89. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001 Mar; 69(3):1643-9.
    View in: PubMed
    Score: 0.010
  90. Chu RS, Askew D, Noss EH, Tobian A, Krieg AM, Harding CV. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 01; 163(3):1188-94.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.